Author

A. Veillette

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:flow cytometry· 1

Frequent Co-Authors

E. Hajaj· 2 shared G. Eisenberg· 2 shared J. E. Cohen· 2 shared M. Lotem· 2 shared N. Hacohen· 2 shared S. Frankenburg· 2 shared S. Klein· 2 shared S. Merims· 2 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Hajaj

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Alternative splicing of SLAMF6 in human T cells creates a co-stimulatory isoform that counteracts the inhibitory effect of the full-length receptor

E. Hajaj, E. Zisman, S. Tzaban, S. Merims, J. E. Cohen, S. Klein, S. Frankenburg, M. Sade-Feldman, Y. Tabach, K. Yizhak, A. Navon, P. Stepensky, N. Hacohen, T. Peretz, A. Veillette, , M. Lotem

This study identifies an alternative splicing event in SLAMF6 that generates a co-stimulatory isoform, which enhances T cell cytotoxicity and is associated with improved anti-tumor responses in melanoma.

bioRxiv · Aug 21, 2020 · PreprintImmunology

When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer

M. S. Hasim, M. Marotel, J. J. Hodgins, E. Vulpis, H.-Y. Shih, A. Scheer, O. MacMillan, F. Alonso, K. Burke, D. P. Cook, M. T. Petrucci, A. Santoni, P. Fallon, A. Sharpe, G. Sciume, , M. Ardolino

Natural Killer cells acquire PD-1 from tumor cells via trogocytosis, which inhibits anti-tumor immunity.

bioRxiv · Jun 26, 2020Immunology

SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a new T cell checkpoint

E. Hajaj, G. Eisenberg, S. Klein, S. Frankenburg, S. Merims, I. Ben David, T. Eisenhaure, S. E. Henrickson, A. C. Villani, N. Hacohen, N. Abudi, R. Abramovich, J. E. Cohen, T. Peretz, A. Veillette, M. Lotem

This study shows that SLAMF6 deficiency enhances T cell tumor-killing ability and shifts T cells toward an effector phenotype, suggesting SLAMF6 as a new immune checkpoint.

bioRxiv · Oct 31, 2019Physiology

Critical role for Slam/SAP signaling in the thymic developmental programming of IL-17- and IFN-γ-producing γδ T cells

O. Dienz, V. L. DeVault, S. C. Musial, S. K. Mistri, L. Mei, A. Baraev, J. A. Dragon, D. Krementsov, A. Veillette, J. E. Boyson

This study shows that SLAM/SAP signaling is critical for thymic development of IL-17 and IFN-γ-producing γδ T cells, with subset-specific dependencies.

bioRxiv · Oct 11, 2019Immunology